Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease

Phase 3

Completed

• Conditions: GERD
• Interventions: Drug: Magnesium Pantoprazole; Drug: Magnesium Esomeprazole

• Registration Number: NCT01132638
• Lead Sponsor: Takeda

Brief Summary

The aim of this trial is to evaluate the complete remission of erosive gastroesophageal reflux disease with pantoprazole magnesium 40 mg once daily versus esomeprazole 40 mg once daily during four-week treatment with an extension treatment for non-responding patients. The study includes a baseline period up to 14 days and a treatment period of either 4 weeks (28 -2 + 5 days), or 8 weeks depending on the cure of esophagitis due to gastroesophageal reflux. The study will provide further data on safety and tolerability of pantoprazole magnesium.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-05-21
• Study First Submitted QC: 2010-05-27
• Study First Posted: 2010-05-28
• Study Start: 2011-08
• Status Verified: 2012-06
• Primary Completion: 2012-06
• Study Completion: 2012-06
• Last Update Submitted: 2012-06-24
• Last Update Posted: 2012-06-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 713

Inclusion Criteria

• Voluntary participation in the study with signature on Informed Consent Form (ICF) prior to specific protocol procedures
• Patients of any race
• On outpatient treatment
• History of frequent symptom crises related to GERD within the last 3 months (at least a frequency of twice a week, for about four to eight weeks)
• Diagnosis of erosive esophagitis (grade A to D, according to Los Angeles Classification)
• In good health condition, except GERD symptoms
• Able to follow the protocol directions and to complete daily the questionnaire ReQuest™ throughout the study

Read More

Exclusion Criteria

• Gastrointestinal disorder, even when related to chlorhydropeptic disorders: Barret's esophagus, peptic ulcer, Zollinger-Ellison syndrome and pyloric stenosis
• Previous history of surgery to reduce acid secretion, or other upper gastrointestinal tract surgeries (excepting polypectomy and cholecystectomy)
• At initial endoscopy presenting complicated disorders due to erosive esophagitis: obstructive esophageal stenoses, Schatzki ring, esophageal diverticulum, esophageal varices, achalasia and hiatal hernia
• Pregnant women or during nursing period
• Proton Pump Inhibitors (PPIs) within the last 10 days prior to start of the study
• Triple therapy based on PPIs to eradicate H. pylori within the last 28 days prior to start of the study
• H2-blockers, sucralfate and prokinetics within the last 7 days prior to start of the study
• Systemic glucocorticoids and/or nonsteroidal anti-inflammatory drugs (including COX-2 inhibitors) for more than 3 consecutive days a week, within the last 28 days prior to start of study, with exception of regular intake of acetyl salicylic acid in dosages of up to 163 mg/day.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Magnesium Pantoprazole	Magnesium Pantoprazole	-
Magnesium Esomeprazole	Magnesium Esomeprazole	-

Primary Outcome Measures

Name	Time	Method
Comparatively evaluation of the clinical efficacy of pantoprazole magnesium and esomeprazole in the treatment of patients with erosive gastroesophageal reflux disease (GERD), considering the proportion of patients in complete remission.	After 4 treatment weeks	A patient is considered at complete remission if he/she achieved symptoms relief and confirmed endoscopic healing at treatment end. A patient achieves symptoms relief if Reflux Questionnaire-GI score ((ReQuest™) stays below 1,73 for at least the three last consecutive treatment days, that can occur at visit V2 or visit V3 for those that did not achieve complete remission at V2 and repeated the treatment for 4 weeks more.

Secondary Outcome Measures

Name	Time	Method
Treatments comparative evaluation for DRGE ReQuest™-GI and -WSO scores change with respect to baseline measured	After 4 and 8 treatment weeks
Treatments comparative evaluation for the time interval from treatment start to the beginning of symptoms relief
Treatments comparative evaluation for endoscopic healing rate	After 4 and 8 treatment weeks

Trial Locations

Locations (1)

Investigational site; 🇧🇷 São Paulo/SP, Brazil